Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Invivyd, Inc.NASDAQ: IVVD
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$98K, compared with $10K a year earlier. Trailing-twelve-month financing cash flow was $215.52M. Over 3 fiscal years it compounded at +652.5% a year.
Context
- Financing cash flow amounted to 403.6% of revenue in FY2025, up 248.7 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$98K or moves back toward the trailing-twelve-month quarterly average of $53.88M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 215.63M USD
- Year-over-year change
- +448.2%
- 4-year CAGR
- -24.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 215.63M | +448.2% |
| FY2024 | 2024-12-31 | 39.33M | +3663.7% |
| FY2023 | 2023-12-31 | 1.05M | +106.5% |
| FY2022 | 2022-12-31 | 506K | -99.9% |
| FY2021 | 2021-12-31 | 662.68M | — |
Financing Cash Flow vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 financing cash flow of $215.52M is the largest of the 10 companies compared; the peer median is $82.13M.
- Its year-over-year change of +89700.8% is the highest of 9, against a peer median of +114.2%.
- Financing cash flow amounts to 385.8% of revenue for IVVD, versus a peer median of 273.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $215.52M | +89700.8% | +652.5% | 385.8% | |
| LTM Mar 2026 | $126.91M | +1085.3% | +379.4% | 364.0% | |
| LTM Sep 2026 | $117.69M | +118.3% | +53.0% | — | |
| LTM Mar 2026 | $94.16M | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $89.31M | +520.7% | -5.8% | 258.5% | |
| LTM Mar 2026 | $82.13M | -42.0% | — | — | |
| LTM Mar 2026 | $27.87M | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $26.83M | -17.0% | — | 34.4% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.21M | -50.6% | -7.8% | 1242.3% |
| LTM Mar 2026 | $16.91M | — | — | — | |
| Peer median (excluding IVVD) | $82.13M | +114.2% | -5.4% | 273.1% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.76M | 21.65M | 18.69M | 19.79M | 11.64M |
| Change in Working Capital | 22.79M | (16.13M) | 5.89M | (23.47M) | (19.69M) |
| Accounts Receivables | 0 | 0 | 0 | (10.91M) | (3.34M) |
| Inventory | 0 | 0 | 0 | (24.89M) | (373K) |
| Accounts Payables | (2.37M) | (4.3M) | 6.47M | 2.42M | 3.21M |
| Other Working Capital | 25.16M | (11.83M) | (583K) | 9.91M | (19.2M) |
| Other Non-Cash Items | 1.5M | 15.35M | (1.12M) | 19.79M | 298K |
| Operating Cash Flow | (184.74M) | (219.99M) | (173.16M) | (170.49M) | (58.14M) |
| Capital Expenditures | (84K) | (1.71M) | (615K) | (140K) | (155K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.63M) | (297.96M) | (91.2M) | 0 | 0 |
| Sales of Investments | 138M | 69M | 372.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71M) | (230.67M) | 280.68M | (140K) | (155K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 330.91M | 510K | 1.2M | 39.29M | 215.63M |
| Common Stock Repurchased | 0 | (4K) | (1K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.39M) | 510K | 1.05M | 46K | 0 |
| Financing Cash Flow | 662.68M | 506K | 1.05M | 39.33M | 215.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 8K | 0 |
| Net Change in Cash | 427.24M | (450.15M) | 108.57M | (131.29M) | 157.34M |
| Free Cash Flow | (184.82M) | (221.69M) | (173.78M) | (170.63M) | (58.29M) |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.